Key Takeaways for GRF Stock as of September 2026
- Beat Despite Revenue Miss: Q2 revenue of €1,874 million missed Street by 0.92% and slipped 0.91% YoY, but EBITDA (€472M, +2.10%), EBIT (€326M, +3.77%) and net income (€133M, +4.40%) all beat.
- FCF Surge: Q2 free cash flow hit €98M, up 227% YoY and 145% above Street’s €40M estimate.
- Guidance Reaffirmed: Management held its full-year target of 25%+ adjusted EBITDA margin and €500M-€575M in free cash flow before M&A, unchanged from prior quarters.
- Confidence Signal: CEO Nacho Abia said the quarter “played out in line with our expectations,” keeping Grifols “firmly on track to deliver our full year 2026 guidance.”
Grifols swung from a revenue miss to a 145% free cash flow beat in one quarter. Explore the full breakdown on TIKR for free →
GRF Stock Jumps 8% as Grifols Turns a Revenue Miss Into a Profit Beat
Grifols (GRF) stock jumped roughly 8% after the company’s Q2 2026 earnings call on July 28, and the reaction traces to a specific mismatch: revenue missed, but nearly every profitability line beat. Second-quarter revenue landed at €1,874 million, 0.92% below the €1,891 million Street estimate and down 0.91% year over year. Yet adjusted EBITDA reached €472 million, 2.10% above estimates, with margin expanding to 25.19%, a 74 basis point beat and a 278 basis point jump from the 22.41% posted in the first quarter.
That margin swing did more than pad the headline number. EBIT climbed to €326 million, 3.77% ahead of Street and up 29.88% sequentially, pushing net income to €133 million, a 4.40% beat. The gap between the softer top line and the stronger bottom line points to a company pricing and allocating plasma more carefully rather than chasing volume. CEO Nacho Abia framed that trade-off directly on the Q2 earnings call: “Our goal is not to maximize volume at any price, but to drive sustainable, profitable and free cash flow growth by focusing on the products, customers and markets where we believe we can create the greatest value.” Immunoglobulin (IG) sales back that up, growing 12.8% at constant currency in the first half while management deliberately dialed back volume in lower-margin markets.
Free cash flow carried the clearest signal. Grifols generated €98 million in the quarter, more than double the €40 million Street expected and up 226.67% from the €30 million posted a year earlier. Management credited disciplined working capital management and the early benefits of its Egypt plasma collection ramp, which is expanding the company’s ex-U.S. sourcing base and cutting reliance on costlier U.S. plasma. Albumin in China stayed a drag, with first-half revenue still reflecting last year’s pricing concession, but management said pricing and prescription trends are stabilizing and expects an easier year-over-year comparison in the second half.
Total net leverage held near 4.2 times, with over €2 billion of liquidity following the refinancing completed earlier in the year. Grifols also confirmed it is evaluating a potential IPO of its U.S. Biopharma unit, though no terms are set. A revenue miss paired with a profitability and cash flow beat, backed by reaffirmed full-year guidance, is the combination that appears to have pushed GRF stock higher.
Grifols generated €98 million in free cash flow, more than double what Street expected. Track the Egypt ramp and margin trend on TIKR for free →
TIKR Values GRF Stock at €16, Pricing In Sustained Margin Discipline
TIKR’s mid-case model values Grifols at €15.64 by December 2030, implying 59.1% total return from the current price of €9.83, or 11.3% annualized over 4.3 years.
That double-digit annualized return marks a real re-rating opportunity for a stock trading well below where the model sees fair value, rewarding investors willing to hold through the multi-year timeline.
The target assumes Grifols keeps converting revenue discipline into margin and cash flow gains at the pace shown this quarter, with EBITDA margin expansion, a mix shift toward higher-margin IG volume and a free cash flow beat that outpaced Street estimates by triple digits all reinforcing that trajectory.
TIKR’s model sees 59% upside to €15.64 for GRF stock by 2030. Build your own valuation case on TIKR for free →
Should You Invest in Grifols, S.A.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up Grifols, S.A. stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Grifols, S.A. alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze GRF stock on TIKR for Free →
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
